NGEN
NervGen Pharma Corp. Common stock
NASDAQ · Healthcare · Biotechnology · CA
$2.33
+0.43%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 12.5K | — | 83.7K | 145.0K | 114.1K |
| Gross Profit | (12.5K) | — | (83.7K) | (145.0K) | (114.1K) |
| Operating Expenses | |||||
| R&D Expense | 24.0M | 13.9M | 15.7M | 8.0M | 16.4M |
| SG&A Expense | 14.0M | 11.2M | 9.2M | 9.6M | 6.3M |
| General & Admin Expense | — | 11.2M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 38.0M | 25.1M | 24.8M | 17.6M | 22.7M |
| Cost and Expenses | 38.1M | 25.1M | 24.9M | 17.8M | 22.8M |
| Operating Income (EBIT) | (38.1M) | (25.1M) | (24.9M) | (17.8M) | (22.8M) |
| Non-Operating | |||||
| Interest Income | 507.6K | 333.4K | 812.1K | 550.1K | 199.6K |
| Interest Expense | — | — | — | — | 510.1K |
| Net Interest Income | 507.6K | 333.4K | 812.1K | 550.1K | (310.4K) |
| Other Non-Op Income/Expense | (29.5M) | (19.0M) | 925.5K | (4.6M) | 2.3M |
| Non-Operating Income (excl Interest) | (26.4M) | (19.4M) | (925.5K) | 4.6M | (2.8M) |
| EBT (Pre-Tax Income) | (67.6M) | (44.1M) | (24.0M) | (22.4M) | (20.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (67.6M) | (44.1M) | (24.0M) | (22.4M) | (20.5M) |
| Earnings from Cont. Ops | (67.6M) | (44.1M) | (24.0M) | (22.4M) | (20.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (67.6M) | (44.1M) | (24.0M) | (22.4M) | (20.5M) |
| Per Share | |||||
| Basic EPS | ($0.85) | ($0.61) | ($0.36) | ($0.37) | ($0.39) |
| Diluted EPS | ($0.85) | ($0.61) | ($0.36) | ($0.37) | ($0.39) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 92.4M | 72.3M | 67.3M | 59.3M | 52.6M |
| Diluted Shares Outstanding | 92.4M | 72.3M | 67.3M | 59.3M | 52.6M |
| Profitability Metrics | |||||
| EBITDA | (11.6M) | (5.7M) | (23.9M) | (22.2M) | (19.9M) |
| D&A | 68.3K | 55.8K | 83.7K | 145.0K | 114.1K |
| EBIT | (11.7M) | (5.7M) | (24.0M) | (22.4M) | (20.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026